Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/alteogens-tergase-novel-recombinant-human-hyaluronidase-injection-shows-excellent-immunogenicity-profile-301916724.html
https://www.prnewswire.com/news-releases/altos-biologics-a-subsidiary-of-alteogen-completed-patient-enrollment-in-global-phase-3-clinical-trial-of-eylea-biosimilar-in-neovascular-age-related-macular-degeneration-301752666.html
https://www.businesswire.com/news/home/20210308005025/en/Alteogen-Announces-Completion-of-Phase-1-Clinical-Trial-of-Aflibercept-Biosimilar-in-Wet-AMD-Patients#:~:text=DAEJEON%2C%20South%20Korea%2D%2D(BUSINESS,Biosimilar%20(ALT%2DL9).&text=Eylea%C2%AE%20is%20a%20drug,along%20with%20cataracts%20and%20glaucoma.
https://www.businesswire.com/news/home/20210107005327/en/Alteogen-Enters-Into-an-Exclusive-License-Agreement-With-Intas-to-Develop-and-Commercialize-Two-Products-Enabled-by-Its-Hybrozyme%E2%84%A2-Technology#:~:text=Business%20Wire-,Alteogen%20Enters%20Into%20an%20Exclusive%20License%20Agreement%20With%20Intas%20to,by%20Its%20Hybrozyme%E2%84%A2%20Technology&text=Under%20the%20terms%20of%20the,in%20combination%20with%20ALT%2DB4.
https://www.businesswire.com/news/home/20200624005349/en/Alteogen-Enters-Global-License-Agreement-Top-Ten